| Style | Citing Format |
|---|---|
| MLA | Freidoon M, et al.. "Association of Interleukin-8 and Neutrophil-To-Lymphocyte Ratio With Clinical Indices in Diabetic Nephropathy." Caspian Journal of Internal Medicine, vol. 17, no. 1, 2026, pp. 191-199. |
| APA | Freidoon M, Kazemzadehghadim H, Assadiasl S, Sayadi N, Soleimanifar N, Sadr M, Mojtahedi H, Nicknam MH (2026). Association of Interleukin-8 and Neutrophil-To-Lymphocyte Ratio With Clinical Indices in Diabetic Nephropathy. Caspian Journal of Internal Medicine, 17(1), 191-199. |
| Chicago | Freidoon M, Kazemzadehghadim H, Assadiasl S, Sayadi N, Soleimanifar N, Sadr M, Mojtahedi H, Nicknam MH. "Association of Interleukin-8 and Neutrophil-To-Lymphocyte Ratio With Clinical Indices in Diabetic Nephropathy." Caspian Journal of Internal Medicine 17, no. 1 (2026): 191-199. |
| Harvard | Freidoon M et al. (2026) 'Association of Interleukin-8 and Neutrophil-To-Lymphocyte Ratio With Clinical Indices in Diabetic Nephropathy', Caspian Journal of Internal Medicine, 17(1), pp. 191-199. |
| Vancouver | Freidoon M, Kazemzadehghadim H, Assadiasl S, Sayadi N, Soleimanifar N, Sadr M, et al.. Association of Interleukin-8 and Neutrophil-To-Lymphocyte Ratio With Clinical Indices in Diabetic Nephropathy. Caspian Journal of Internal Medicine. 2026;17(1):191-199. |
| BibTex | @article{ author = {Freidoon M and Kazemzadehghadim H and Assadiasl S and Sayadi N and Soleimanifar N and Sadr M and Mojtahedi H and Nicknam MH}, title = {Association of Interleukin-8 and Neutrophil-To-Lymphocyte Ratio With Clinical Indices in Diabetic Nephropathy}, journal = {Caspian Journal of Internal Medicine}, volume = {17}, number = {1}, pages = {191-199}, year = {2026} } |
| RIS | TY - JOUR AU - Freidoon M AU - Kazemzadehghadim H AU - Assadiasl S AU - Sayadi N AU - Soleimanifar N AU - Sadr M AU - Mojtahedi H AU - Nicknam MH TI - Association of Interleukin-8 and Neutrophil-To-Lymphocyte Ratio With Clinical Indices in Diabetic Nephropathy JO - Caspian Journal of Internal Medicine VL - 17 IS - 1 SP - 191 EP - 199 PY - 2026 ER - |